Ilaria Colombo

1.2k total citations
63 papers, 656 citations indexed

About

Ilaria Colombo is a scholar working on Oncology, Molecular Biology and Reproductive Medicine. According to data from OpenAlex, Ilaria Colombo has authored 63 papers receiving a total of 656 indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Oncology, 17 papers in Molecular Biology and 16 papers in Reproductive Medicine. Recurrent topics in Ilaria Colombo's work include Ovarian cancer diagnosis and treatment (16 papers), PARP inhibition in cancer therapy (11 papers) and Cancer Immunotherapy and Biomarkers (9 papers). Ilaria Colombo is often cited by papers focused on Ovarian cancer diagnosis and treatment (16 papers), PARP inhibition in cancer therapy (11 papers) and Cancer Immunotherapy and Biomarkers (9 papers). Ilaria Colombo collaborates with scholars based in Switzerland, Italy and Canada. Ilaria Colombo's co-authors include Federica Martorana, Amit M. Oza, Cristiana Sessa, Giovanna Damia, Francesco Bertoni, Michela Chiappa, Federica Guffanti, Anastasios Stathis, David G. Farrar and Stéphanie Lheureux and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and American Journal of Epidemiology.

In The Last Decade

Ilaria Colombo

56 papers receiving 652 citations

Peers

Countries citing papers authored by Ilaria Colombo

Since Specialization

Citations

This map shows the geographic impact of Ilaria Colombo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ilaria Colombo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ilaria Colombo more than expected).

Fields of papers citing papers by Ilaria Colombo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ilaria Colombo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ilaria Colombo. The network helps show where Ilaria Colombo may publish in the future.

Co-authorship network of co-authors of Ilaria Colombo

This figure shows the co-authorship network connecting the top 25 collaborators of Ilaria Colombo. A scholar is included among the top collaborators of Ilaria Colombo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ilaria Colombo. Ilaria Colombo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Safety of antibody-drug conjugates in gynecologic cancers: current evidence and management approaches 2025 ·International Journal of Gynecological Cancer ·(unknown), (unknown), Stéphanie Lheureux, Toon Van Gorp, Ilaria Colombo, Ainhoa Madariaga	0
2	TLD-1, a novel liposomal doxorubicin, in patients with advanced solid tumors: Dose escalation and expansion part of a multicenter open-label phase I trial (SAKK 65/16) 2024 ·European Journal of Cancer ·Ilaria Colombo, (unknown), (unknown), Simon Haefliger, Manuela Rabaglio, Sara Bastian, (unknown), Katrin Eckhardt, Stefanie Hayoz, (unknown), Charlotte Kloft, (unknown), (unknown), Christian Baumgärtner, Cristiana Sessa, Anastasios Stathis, Dagmar Hess, Markus Joerger	10
3	Results of a phase 1, dose-finding study of Debio 0123 as monotherapy in adult patients with advanced solid tumors: Safety, pharmacokinetic, and preliminary antitumor activity data. 2024 ·Journal of Clinical Oncology ·Kyriakos P. Papadopoulos, Manish Sharma, Reinhard Dummer, Ilaria Colombo, Egle Ramelyte, Leigh G. Seamon, Drew Rasco, (unknown), (unknown), Tri Tat, (unknown), (unknown), (unknown), Sandrine Micallef, Anne Bellon, (unknown), Anastasios Stathis	5
4	Antibody-Drug Conjugates in Ovarian Cancer: Promises and Challenges 2023 ·SHILAP Revista de lepidopterología ·(unknown), (unknown), Ilaria Colombo	2
5	Whole-Body Composition Features by Computed Tomography in Ovarian Cancer: Pilot Data on Survival Correlations 2023 ·Cancers ·(unknown), Maria Del Grande, Ilaria Colombo, (unknown), Lucia Manganaro, Maria Luisa Gasparri, Andrea Papadia, Filippo Del Grande, Stefania Rizzo	2
6	1037P Phase I dose-escalation trial with tumor-targeted interleukin-12 (IL12-L19L19) in patients with solid tumors 2023 ·Annals of Oncology ·Nicolas Mach, Carmen Belli, Eduardo Fernández, Winfried Alsdorf, Ilaria Colombo, (unknown), (unknown), Emanuele Puca, (unknown), (unknown), (unknown), K. Lorizzo, Dario Neri, A. Covelli, Ulrich M. Lauer, (unknown), Anastasios Stathis, Walter Fiedler, Giuseppe Curigliano	2
7	50P Can we learn from failures? A systematic review and metanalysis of phase III trials in platinum resistant ovarian cancer 2023 ·ESMO Open ·Federica Martorana, Cristiana Sessa, Stéphanie Lheureux, Ilaria Colombo	1
8	The clinical challenges of homologous recombination proficiency in ovarian cancer: from intrinsic resistance to new treatment opportunities 2023 ·Cancer Drug Resistance ·(unknown), Sana Intidhar Labidi‐Galy, Maria Del Grande, Cristiana Sessa, Ilaria Colombo	6
9	Everything Comes with a Price: The Toxicity Profile of DNA-Damage Response Targeting Agents 2022 ·Cancers ·Federica Martorana, (unknown), Cristiana Sessa, Ilaria Colombo	34
10	Phase I Dose-Escalation Study of the Dual PI3K-mTORC1/2 Inhibitor Gedatolisib in Combination with Paclitaxel and Carboplatin in Patients with Advanced Solid Tumors 2021 ·Clinical Cancer Research ·Ilaria Colombo, Sofia Genta, Federica Martorana, Monia Guidi, Milo Frattini, Eleftherios Pierre Samartzis, Simone Brandt, (unknown), (unknown), Mariarosa Pascale, Tatiana Terrot, Cristiana Sessa, Anastasios Stathis	27
11	A systematic review of phase II trials exploring anti-PD-1/PD-L1 combinations in patients with solid tumors 2021 ·Cancer Treatment Reviews ·Federica Martorana, Ilaria Colombo, Giorgio Treglia, Silke Gillessen, Anastasios Stathis	10
12	Binimetinib, pemetrexed and cisplatin, followed by maintenance of binimetinib and pemetrexed in patients with advanced non-small cell lung cancer (NSCLC) and KRAS mutations. The phase 1B SAKK 19/16 trial 2021 ·Lung Cancer ·Patrizia Froesch, Michael Mark, Sacha I. Rothschild, Qiyu Li, Gilles Godar, Corinne Rusterholz, Elisabeth Oppliger Leibundgut, Sabine Schmid, Ilaria Colombo, Yannis Metaxas, David König, Cristiana Sessa, Oliver Gautschi, Martin Früh	14
13	575P TLD-1, a novel liposomal doxorubicin, in patients (pts) with advanced solid tumours: Dose escalation part of a multicenter open-label phase I trial (SAKK 65/16) 2020 ·Annals of Oncology ·Dagmar Hess, Ilaria Colombo, Simon Haefliger, Sara Bastian, Manuela Rabaglio, Yannis Metaxas, Klaus Eckhardt, Christoph Kopp, Stefanie Hayoz, (unknown), Charlotte Kloft, Cristiana Sessa, Anastasios Stathis, Markus Joerger	2
14	Targeting the DNA damage response for patients with lymphoma: Preclinical and clinical evidences 2020 ·Cancer Treatment Reviews ·Laura Carrassa, Ilaria Colombo, Giovanna Damia, Francesco Bertoni	16
15	568P Phase I dose-escalation study of the dual PI3K/mTORC1/2 inhibitor Gedatolisib (PF-05212384) in combination with paclitaxel (P) and carboplatin (C) in patients (pts) with advanced solid tumours 2020 ·Annals of Oncology ·Ilaria Colombo, Sofia Genta, Federica Martorana, Monia Guidi, (unknown), Simone Brandt, (unknown), (unknown), Mariarosa Pascale, Tatiana Terrot, Cristiana Sessa, Anastasios Stathis	3
16	557P Binimetinib, pemetrexed (Pem) and cisplatin (Cis), followed by maintenance of Binimetinib and Pem in patients with advanced non-small cell lung cancer (NSCLC) and KRAS mutations: The phase Ib SAKK 19/16 trial 2020 ·Annals of Oncology ·Patrizia Froesch, Michael Mark, Sacha I. Rothschild, (unknown), Gilles Godar, Corinne Rusterholz, Sabine Schmid, Ilaria Colombo, Yannis Metaxas, Helen Thut, C. Sessa, Oliver Gautschi, Martin Früh	1
17	562P Target engagement and clinical safety of CB-103, a first-in-class small molecule inhibitor of the NOTCH transcription complex 2020 ·Annals of Oncology ·(unknown), José Manuel Pérez García, Javier Cortés, Elena Miranda, Ilaria Colombo, Elena Garralda, Dagmar Hess, Paolo Nucíforo, Ana Vivancos, (unknown), Oliver Schönborn‐Kellenberger, Karin Jorga, (unknown), (unknown), Rajwinder Lehal, Maximilien Murone, Michael Bauer, Pavel Pisa, Florian D. Vogl, Anastasios Stathis	1
18	Heterogeneous alteration of the ERBB3–MYC axis associated with MEK inhibitor resistance in a KRAS-mutated low-grade serous ovarian cancer patient 2019 ·Molecular Case Studies ·Ilaria Colombo, Swati Garg, Arnavaz Danesh, Jeffrey P. Bruce, Patricia Shaw, Qian Tan, Rene Quevedo, Marsela Braunstein, Amit M. Oza, Trevor J. Pugh, Stéphanie Lheureux	8
19	Rucaparib: a novel PARP inhibitor for <em>BRCA</em> advanced ovarian cancer 2018 ·Drug Design Development and Therapy ·Ilaria Colombo, Stéphanie Lheureux, Amit M. Oza	30
20	Molecular imaging in drug development: Update and challenges for radiolabeled antibodies and nanotechnology 2017 ·Methods ·Ilaria Colombo, Marta Overchuk, Juan Chen, Raymond M. Reilly, Gang Zheng, Stéphanie Lheureux	26

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact